The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes
Science Immunology · 10.07.2026 · 11 (121)
DOI: 10.1126/sciimmunol.adz2494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 10.07.2026. Verfasst von Yumin Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Host Defenses, Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Kore…. Hauptthemen laut MEDLINE: Glioblastoma, B-Lymphocytes, Immune Checkpoint Inhibitors, CTLA-4 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Research Foundation of Korea, Samsung Science and Technology Foundation.
Abstract (Originalsprache)
Humoral immunity, mediated by B cells that mature in germinal centers in lymph nodes (LNs), is essential for adaptive immune responses, but its role in antitumor immunity and responses to immunotherapy remain unclear. Here, we show that activation of B cells in tumor-draining deep cervical LNs (dcLNs) is necessary for the efficacy of CTLA-4 (cytotoxic T lymphocyte–associated protein 4) immune checkpoint blockade in glioma in vivo. Anti–CTLA-4 therapy enhanced T follicular helper cell (T FH cell) expansion in dcLNs, leading to germinal center B cell responses, immunoglobulin G (IgG) class switching, and the generation of glioma-reactive antibodies. Glioma-bearing mice lacking antibody-secreting cells did not benefit from CTLA-4 blockade. Distally secreted IgG accumulated in the tumor microenvironment and promoted glioma cell phagocytosis in vivo. These findings define a B cell–dependent mechanism underlying CTLA-4–mediated control of glioma and provide a conceptual framework for future therapeutic strategies in tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Host Defenses, Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
- Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
- Department of Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
- Regenerative Medical Research Institute (reMRI) for Aging-Related Diseases, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
ORCID-Profile: Yumin Kim, In Kang, Byeong Hoon Kang, Won Hyung Park, Chae Won Kim, Hyun-Jin Kim, Jeongwoo La, Myoung Seung Kwon, Sang Hee Park, Seo Hyeon Im, Hyeon Cheol Kim, Keun Bon Ku, Minji Kim, Ji Eun Oh, Heung Kyu Lee
Förderung
- National Research Foundation of Korea
- Samsung Science and Technology Foundation
Zitieren
APA
Kim, Y., Kang, I., Kang, B. H., Park, W. H., Kim, C. W., Kim, H. J., La, J., Kwon, M. S., Park, S. H., Im, S. H., Kim, H. C., Ku, K. B., Kim, M., Oh, J. E., & Lee, H. K. (2026). The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science Immunology, 11(121). https://doi.org/10.1126/sciimmunol.adz2494
Vancouver
Kim Y, Kang I, Kang BH, Park WH, Kim CW, Kim HJ, et al. The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science Immunology. 2026;11(121). doi:10.1126/sciimmunol.adz2494
BibTeX
@article{Kim2026,
author = {Kim, Yumin and Kang, In and Kang, Byeong Hoon and Park, Won Hyung and Kim, Chae Won and Kim, Hyun-Jin and La, Jeongwoo and Kwon, Myoung Seung and Park, Sang Hee and Im, Seo Hyeon and Kim, Hyeon Cheol and Ku, Keun Bon and Kim, Minji and Oh, Ji Eun and Lee, Heung Kyu},
title = {The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes},
journal = {Science Immunology},
year = {2026},
volume = {11},
number = {121},
doi = {10.1126/sciimmunol.adz2494}
}
EUVIMED